Literature DB >> 2295073

Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D.

A Mullick1, P Chambon.   

Abstract

Drug resistance occurs frequently during breast cancer treatment with antiestrogens. Since antiestrogen action is mediated by the estrogen receptor (ER), we have examined both the structural and functional properties of the ER present in two breast cancer cell lines, LY2 and T47D, which proliferate rapidly in the presence of antiestrogens. The ER function in LY2 cells was indistinguishable from that of the parental tamoxifen-sensitive MCF-7 cells as assessed by estrogen regulation of two endogenous genes and estrogen-regulated transcription in a transient transfection system. RNase protection assays, sensitive enough to detect single base pair mismatches, showed that the sequence of the coding region of ER of LY2 and T47D cells was wild type. Thus the ER appears to be normal in two independently isolated breast cancer cell lines whose growth is resistant to the inhibitory effect of antiestrogens. Moreover by conducting the cell proliferation studies in a phenol red-free medium, we have demonstrated that the antiestrogen resistance of LY2 and T47D cells corresponds in fact to an estrogen-independent growth.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295073

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.

Authors:  Tissa T Manavalan; Yun Teng; Savitri N Appana; Susmita Datta; Theodore S Kalbfleisch; Yong Li; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2011-09-10       Impact factor: 8.679

2.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

Review 3.  Hormone resistance, invasiveness, and metastatic potential in breast cancer.

Authors:  R Clarke; E W Thompson; F Leonessa; J Lippman; M McGarvey; T L Frandsen; N Brünner
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation.

Authors:  J J Pink; M M Bilimoria; J Assikis; V C Jordan
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

Review 5.  William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells.

Authors:  A de Cupis; D Noonan; P Pirani; A Ferrera; L Clerico; R E Favoni
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

7.  GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells.

Authors:  Jessica L Schwartz-Roberts; Ayesha N Shajahan; Katherine L Cook; Anni Wärri; Mones Abu-Asab; Robert Clarke
Journal:  Mol Cancer Ther       Date:  2013-02-08       Impact factor: 6.261

Review 8.  Molecular mechanisms of antiestrogen action in breast cancer.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 9.  Antiestrogen resistance in ER positive breast cancer cells.

Authors:  S Paik; D P Hartmann; R B Dickson; M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 10.  Oestrogen receptor: a stable phenotype in breast cancer.

Authors:  J F Robertson
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.